• Careers
  • Support

ATCC Announces New Immuno-oncology CAR-T Target Luciferase Reporter Cell Lines to Enable Discovery and Development of Immunotherapies

News Release
CAR-T cells, CAR-Target, CD19, CD20, HER2

ATCC to provide more physiologically relevant immuno-oncology tools for better reproducibility and improved in vitro targeting to facilitate the advancement of novel cancer treatments.

Manassas, VA, United States

November 03, 2022
ATCC, the world’s premier biological materials management and standards organization, today announced a new line of products, CAR-T Target luciferase reporter cell lines, that will support immuno-oncology (IO) discovery and development of novel immunotherapies. These models have a high endogenous expression of relevant chimeric antigen receptor (CAR)-T target antigens such as HER2, CD19, and CD20. These new IO tools are comprised of both hematological cancer and solid tumor cell lines that express a luciferase reporter.

“At ATCC, our mission is to offer the scientific community credible biological products that support incredible achievements in basic science, drug discovery, translational medicine, and public health,” said Raymond H. Cypess, D.V.M., Ph.D., chairman and CEO of ATCC. “We believe that these innovative CAR-T target cell lines will help mitigate some of the formidable roadblocks that IO researchers encounter in their fight against cancer.”

These new IO tools alleviate many of the challenges in evaluating the ex vivo biofunction of CAR-T cells. Coming from highly authenticated and characterized human ATCC cell lines eliminates questions of cell provenance, as well as potential donor-to-donor and cross-species issues. In addition, these lines stably express a sensitive, robust, and easy-to-use reporter system and have been shown in a recent study to display dose-dependent targeting. 

“As IO is one of the fastest growing sectors in cancer research and therapeutics, ATCC continues to prioritize the development of solutions to support the global effort in advancing this field,” said Fang Tian, Ph.D., director of Biological Content.

ATCC supports cancer research and drug discovery with thousands of human and animal cancer cell lines for a better understanding of tumor biology, cancer genomics, tumor biomarkers, and advancing novel therapeutics. In addition to providing the most commonly used historical tumor cell lines, ATCC develops genetically engineered cell lines, tumor organoids, reporter cell lines, and drug-resistant cell lines for the global scientific community. 

ATCC will be showcasing its immuno-oncology research tools at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting in Boston, Massachusetts, November 8 through November 12, 2022. At booth 313, they will present the poster, “Luciferase reporter cancer cell lines facilitate CAR-T development.”

About ATCC

ATCC is a premier global biological materials and information resource and standards organization and the leading developer and supplier of authenticated cell lines, microorganisms, and associated data for academia, industry, and government. With a history of scientific contributions spanning nearly a century, ATCC offers an unmatched combination of being the world’s largest and most diverse collection of biological reference materials and data, and is a mission-driven, trusted partner that supports and encourages scientific collaboration. ATCC products, services, partnerships, and people provide the global scientific community with credible, advanced, model systems to support complex research and innovations in basic science, drug discovery, translational medicine, and public health. ATCC is a 501(c)3 nonprofit organization with headquarters in Manassas, Virginia, and a research and technology center of excellence in Gaithersburg, Maryland. 

Contact: Kim Testa, senior director, Corporate Communications & Public Affairs, ATCC, [email protected]